Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
granulocyte-colony stimulating factor + erythropoietin
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Granulocyte-colony stimulating factor (G-CSF) and erythropoietin (EPO) is a combination therapy involving two hematopoietic growth factors. G-CSF stimulates the bone marrow to produce neutrophils, increasing white blood cell counts and reducing infection risk, especially after chemotherapy or in cases of neutropenia. Erythropoietin stimulates red blood cell production by acting on erythroid progenitor cells in the bone marrow. The combination has been studied for synergistic effects in various conditions including myelodysplastic syndromes (MDS), where it can improve anemia and reduce transfusion needs, as well as for neuroprotection and functional recovery after stroke. Clinical studies have shown that this combination can safely elevate both white and red blood cell counts without major adverse events[1][2].
- Brand names
- NeupogenNivestymZarxioReleuko
- Other names
- G-CSF + EPOerythropoietin + granulocyte-colony stimulating factor
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)Erythropoietin Receptor
Beyond the preview
Go deeper on granulocyte-colony stimulating factor + erythropoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on granulocyte-colony stimulating factor + erythropoietin.